In Brief This Week: Miraculins, Alere; LabCorp; Plasticell, Pfizer, Cellzome | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Miraculins said today that Alere has secured a second exclusive option period on Miraculins' preeclampsia technology and will provide Miraculins a non-refundable fee. Under the terms of the original agreement signed two years ago, Alere is working towards the goal of commercializing Miraculins' preeclampsia technology for worldwide distribution.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.